115 related articles for article (PubMed ID: 16179870)
1. Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases.
Kirschner M; Helmke B; Starz H; Benner A; Thome M; Deichmann M
Melanoma Res; 2005 Oct; 15(5):427-34. PubMed ID: 16179870
[TBL] [Abstract][Full Text] [Related]
2. Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases.
Deichmann M; Thome M; Benner A; Kirschner M; Hassanzadeh J; Kurzen H
BMC Cancer; 2005 Jun; 5():58. PubMed ID: 15935100
[TBL] [Abstract][Full Text] [Related]
3. B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.
Deichmann M; Thome M; Benner A; Näher H
Oncology; 2004; 66(5):411-9. PubMed ID: 15331929
[TBL] [Abstract][Full Text] [Related]
4. The oncogenic B-raf V599E mutation occurs more frequently in melanomas at sun-protected body sites.
Deichmann M; Krahl D; Thome M; Wüst K; Hassanzadeh J; Helmke B
Int J Oncol; 2006 Jul; 29(1):139-45. PubMed ID: 16773193
[TBL] [Abstract][Full Text] [Related]
5. Detection of B-RAF and N-RAS mutations in human melanoma.
Goydos JS; Mann B; Kim HJ; Gabriel EM; Alsina J; Germino FJ; Shih W; Gorski DH
J Am Coll Surg; 2005 Mar; 200(3):362-70. PubMed ID: 15737846
[TBL] [Abstract][Full Text] [Related]
6. Lack of BRAF mutations in uveal melanoma.
Rimoldi D; Salvi S; Liénard D; Lejeune FJ; Speiser D; Zografos L; Cerottini JC
Cancer Res; 2003 Sep; 63(18):5712-5. PubMed ID: 14522889
[TBL] [Abstract][Full Text] [Related]
7. The RAS-BRAF kinase pathway is not involved in uveal melanoma.
Kiliç E; Brüggenwirth HT; Verbiest MM; Zwarthoff EC; Mooy NM; Luyten GP; de Klein A
Melanoma Res; 2004 Jun; 14(3):203-5. PubMed ID: 15179189
[TBL] [Abstract][Full Text] [Related]
8. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
Sharma A; Trivedi NR; Zimmerman MA; Tuveson DA; Smith CD; Robertson GP
Cancer Res; 2005 Mar; 65(6):2412-21. PubMed ID: 15781657
[TBL] [Abstract][Full Text] [Related]
9. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
[TBL] [Abstract][Full Text] [Related]
10. BRAF mutations in metastatic melanoma: a possible association with clinical outcome.
Kumar R; Angelini S; Czene K; Sauroja I; Hahka-Kemppinen M; Pyrhönen S; Hemminki K
Clin Cancer Res; 2003 Aug; 9(9):3362-8. PubMed ID: 12960123
[TBL] [Abstract][Full Text] [Related]
11. Tandem BRAF mutations in primary invasive melanomas.
Thomas NE; Alexander A; Edmiston SN; Parrish E; Millikan RC; Berwick M; Groben P; Ollila DW; Mattingly D; Conway K
J Invest Dermatol; 2004 May; 122(5):1245-50. PubMed ID: 15140228
[TBL] [Abstract][Full Text] [Related]
12. Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma.
Maat W; Kilic E; Luyten GP; de Klein A; Jager MJ; Gruis NA; Van der Velden PA
Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):23-7. PubMed ID: 18172070
[TBL] [Abstract][Full Text] [Related]
13. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues.
Gorden A; Osman I; Gai W; He D; Huang W; Davidson A; Houghton AN; Busam K; Polsky D
Cancer Res; 2003 Jul; 63(14):3955-7. PubMed ID: 12873990
[TBL] [Abstract][Full Text] [Related]
14. No evidence for mutation of B-RAF in urothelial carcinomas of the bladder and upper urinary tract.
Stoehr R; Brinkmann A; Filbeck T; Gamper C; Wild P; Blaszyk H; Hofstaedter F; Knuechel R; Hartmann A
Oncol Rep; 2004 Jan; 11(1):137-41. PubMed ID: 14654916
[TBL] [Abstract][Full Text] [Related]
15. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis.
Ugurel S; Thirumaran RK; Bloethner S; Gast A; Sucker A; Mueller-Berghaus J; Rittgen W; Hemminki K; Becker JC; Kumar R; Schadendorf D
PLoS One; 2007 Feb; 2(2):e236. PubMed ID: 17311103
[TBL] [Abstract][Full Text] [Related]
16. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
Clin Cancer Res; 2003 Dec; 9(17):6483-8. PubMed ID: 14695152
[TBL] [Abstract][Full Text] [Related]
17. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
[TBL] [Abstract][Full Text] [Related]
18. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.
van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA
Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725
[TBL] [Abstract][Full Text] [Related]
19. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
[TBL] [Abstract][Full Text] [Related]
20. Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma.
van Dijk MC; Bernsen MR; Ruiter DJ
Am J Surg Pathol; 2005 Sep; 29(9):1145-51. PubMed ID: 16096402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]